Latvian Institute of Organic Synthesis is a member of the ENABLE consortium since 2014.
The ENABLE consortium is working to advance the development of promising new antibiotic compounds targeting Gram-negative bacteria such as Escherichia coli. The goal of the project is to develop attractive antimicrobial candidates for extensive preclinical studies and First-in-Human clinical trials, bringing new antibiotics to treat Gram-negative infections one step closer to patients.
The video introduces ENABLE, its drug discovery platform, expert network and explains how to submit an Expression of Interest (EoI).